State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS)
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
PCOS, a heterogeneous disorder characterized by cystic ovarian morphology, androgen excess, and/or irregular periods, emerges during or shortly after puberty. Peri- and post-pubertal obesity, insulin resistance and consequent hyperinsulinemia are highly prevalent co-morbidities of PCOS and promote an ongoing state of excess androgen. Given the relationship of insulin to androgen excess, reduction of insulin secretion and/or improvement of its action at target tissues offer the possibility of improving the physical stigmata of androgen excess by correction of the reproductive dysfunction and preventing metabolic derangements from becoming entrenched. While lifestyle changes that concentrate on behavioral, dietary and exercise regimens should be considered as first line therapy for weight reduction and normalization of insulin levels in adolescents with PCOS, several therapeutic options are available and in wide use, including oral contraceptives, metformin, thiazolidenediones and spironolactone. Overwhelmingly, the data on the safety and efficacy of these medications derive from the adult PCOS literature. Despite the paucity of randomized control trials to adequately evaluate these modalities in adolescents, their use, particularly that of metformin, has gained popularity in the pediatric endocrine community. In this article, we present an overview of the use of insulin sensitizing medications in PCOS and review both the adult and (where available) adolescent literature, focusing specifically on the use of metformin in both mono- and combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“Whereas the degree of IR in PCOS is greater than that predicted by BMI alone, nearly half of PCOS women are not obese [129] and the degree of visceral adiposity alone is inadequate to explain differences in insulin sensitivity between PCOS and normal women, suggesting that weight loss by itself may be insufficient to…”
BackgroundAmenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121 · cited 1×
“The association between disordered carbohydrate metabolism and excessive androgen action in women was first reported in 1921 [26] as “the diabetes of bearded women (diabète des femmes à barbe)”, preceding Stein and Leventhal’s formal description of PCOS [27].”
BackgroundProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“In addition, the typically gradual transition from impaired glucose tolerance (IGT) to overt T2DM may be accelerated 5 to 10-fold in women with PCOS [20,21].”
BackgroundMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · cited 1×
“These associated metabolic derangements greatly increase a woman’s lifetime risk to develop T2DM and cardiovascular co-morbidities [23,24].”
BackgroundKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Cited by
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dsc · Cited by 623
Asemi, Z., & Esmaillzadeh, A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1376990 · Cited by 134
“Increased understanding of the role of insulin resistance in the pathogenesis of PCOS has led to the development of new strategies, including dietary modifica - tions, in the treatment of PCOS [11].”
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12294 · Cited by 105
Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome
Nandalike, K., Agarwal, C., Strauss, T., Coupey, S. M., Isasi, C. R., Sin, S., & Arens, R. (2012) · Sleep Medicine · doi:10.1016/j.sleep.2012.07.002 · Cited by 68
PCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Metadata
- Authors
- of the Drug and Therapeutics Committee of the Pediatric Endocrine Society, Geller, D. H., Pacaud, D., Gordon, C. M., & Misra, M.
- Venue
- International Journal of Pediatric Endocrinology
- Published
- 2011-08-26
- Volume
- 2011
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1687-9848 (ISSN-L)
- 1687-9856
- OpenAlex
- W2157202918
- Cited by
- 72
- References
- 59
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). https://app.cochat.ai/papers/10.1186/1687-9856-2011-9
- The paper
- of the Drug and Therapeutics Committee of the Pediatric Endocrine Society, Geller, D. H., Pacaud, D., Gordon, C. M., & Misra, M. (2011). State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). International Journal of Pediatric Endocrinology. https://doi.org/10.1186/1687-9856-2011-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.